IRIS Protocol has launched a fixed-rate borrowing layer on top of SparkLend's variable-rate market, allowing borrowers to lock in interest rates for periods from one to 90 days. Borrowers submit loan requests with their terms, and competing solvers bid to offer fixed-rate quotes, taking on the risk of fluctuating variable rates. This model provides borrowers with predictable borrowing costs and introduces a new business opportunity for solvers who manage the underlying variable-rate positions. The system uses an off-chain request-for-quote process and does not rely on fixed-rate liquidity pools, instead drawing capital from the existing SparkLend market. The success of IRIS will depend on solver participation and how much borrowing volume it can capture from SparkLend's $2.64 billion outstanding loans.
IRIS Protocol's new fixed-rate borrowing layer on SparkLend's market aims to capture part of SparkLend's $2.64 billion outstanding loans. For readers following the cryptocurrency sector, here is Pluang's market snapshot as of Nov 09, 2026 20:02 WIB: out of 50 major cryptocurrencies, 17 rose and 32 fell today. Notable movers include BAL (Balancer) up 11.14% to Rp16.297, EOS (EOS.IO) up 8.13% to Rp12.649, and ONE (Harmony) down 20.74% to Rp27 with a typical hold time of 153 days and a Pluang order activity split of 51% Sell / 49% Buy.
Neo Security, Inc. has launched Neoverse, a free AI software intelligence engine that researches and classifies over 4 million AI apps, extensions, and servers to assess their capabilities and security risks. Integrated into Neo's platform, Neoverse ...
AnorTech Inc. completed a $7.55 million share exchange with Nasdaq-listed Greenland Mines, increasing Greenland Mines' ownership in AnorTech to 19.9%. Greenland Mines acquired over 25 million AnorTech shares in exchange for Greenland Mines shares val...
Microsoft will retire the backend services for its UWP Map Control and Windows Maps APIs on November 30, 2026, ending map functionality in many Windows desktop and tablet applications. OnTerra Systems, a Microsoft partner, has developed an off-the-sh...
Marengo Therapeutics presented interim Phase 2 results from the STARt-002 trial combining invikafusp alfa, a selective T-cell agonist, with sacituzumab govitecan in metastatic triple-negative and HR-positive/HER2-negative breast cancer. The trial sho...
Holzer & Holzer, LLC announced deadlines for investors to seek lead plaintiff status in shareholder class action lawsuits against The Ensign Group, Netcapital Inc., and Webull Corporation. These lawsuits allege misleading statements and failure to di...
